Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.42 |
| ▸ | CETP | P11597 | 12/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898562 | 0.88 | CETP (0.53) | CETP | |
| SCHEMBL1898564 | 0.81 | TACR1 (0.40) | GPBAR1TACR1RXRARXRBRXRG | |
| SCHEMBL16279935 | 0.79 | GPBAR1 (0.41) | GPBAR1CETPTACR1 | |
| SCHEMBL5670182 | 0.77 | CETP (0.36) | GPBAR1CETPTACR1RXRARXRG | |
| SCHEMBL5669596 | 0.71 | CETP (0.46) | GPBAR1CETPTACR1 | |
| SCHEMBL5669323 | 0.70 | CETP (0.50) | GPBAR1CETPTACR1 | |
| SCHEMBL16279588 | 0.70 | CETP (0.42) | GPBAR1CETP | |
| SCHEMBL16280127 | 0.70 | GPBAR1 (0.41) | GPBAR1CETPTACR1 | |
| SCHEMBL5148391 | 0.70 | GPBAR1 (0.48) | GPBAR1CETPTACR1 | |
| SCHEMBL5148326 | 0.69 | TACR1 (0.39) | TACR1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | GPBAR1 329/4885CETP 1/4885TACR1 1329/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | GPBAR1 329/4885CETP 1/4885TACR1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.